1 Olin, JW and BA Sealove. Peripheral Artery Disease: Current Insight into the Disease and Its Diagnosis and ManIkäment. Mayo Clin Proc. 2010;85(7):678-692.
2 Tunstall-Pedoe, H et al. Twenty-Year Predictors of Peripheral Arterial Disease Compared With Coronary Heart Disease in the Scottish Heart Health Extended Cohort (SHHEC). J Am Heart Assoc. 2017;6:e005967.
3 Thiruvoipati, T et al. Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes. 2015;6(7):961-969.
4 Sharma, A. et al. (2014). Atherosclerotic peripheral arterial disease of the lower extremities: What every primary care physician should know. Consultant, 54(7): 537-541
5 Olin, J. W. et al. (2010). Peripheral Artery Disease: Current Insight into the Disease and Its Diagnosis and ManIkäment. Mayo Clin Proc, 85(7), 678–692.
6 What is Korkea verenpaine? American Heart Association. http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/GettheFactsAboutHighBloodPressure/What-is-High-Blood-Pressure_UCM_301759_Article.jsp#.WrqtReR1rcs. Accessed March 9, 2018.
9 Selvin, E. et al. (2004). Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation, 110(6), 738-743.
10 Khaleghi, M. et al. (2014). Family History as a Risk Factor for Peripheral Arterial Disease. Am J Cardiol, 114(6), 928–932.
11Allison, M. A., Ho, E., Denenberg, J. O., Langer, R. D., Newman, A. B., Fabsitz, R. R., & Criqui, M. H. (2007). Ethnic-specific prevalence of peripheral arterial disease in the United States. American journal of preventive medicine, 32(4), 328-333
12 Gerhard, Herman MD et al. 2016 AHA/ACC Guideline on the Mangement of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. Circ. 2016; 138(2):1 273.
13 Hardman, RL et al. Overview of Classification Systems in Peripheral Artery Disease. Semin Intervent Radiol. 2014; 31(4):378–388.
14 Hirsch, AT et al. ACC/AHA 2005 Practice Guidelines for the ManIkäment of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). Circ. 2006;113:e463-e654
15 Swaminathan, A. et al. Lower extremeity amputation in peripherial arterial disease: improving patient outcomes. Vasc Health Risk Manag. 2014: 10: 417-424
16 Allie, DE et al. 24-carat gold, 14-carat gold, or platinum standards in the Hoito of critical limb ischemia: bypass surgery or endovascular intervention?. J Endovasc Ther. 2009;16:134-146.
17 Goodney PP et al. Variation in the Use of Lower Extremity Vascular Procedures for Critical Limb Ischemia. Circ-Cardiovasc Qual. 2012;5(1):94-102.
18 Bhara, M et al. How To Form A Diabetic Limb SalvIkä Team. Podiatry Today. 2010;23(6).
19 Driver, VR et al. The costs of diabetic foot: The economic case for the limb salvIkä team. J Vasc Surg. 2010;9:17S-22S.
*20Barshes, NR et al. Cost-effectiveness in the contemporary manIkäment of critical limb ischemia with tissue loss. J Vasc Surg. 2012;56(4), 1015-1024.
21 Yost ML, The SIkä Group (2014) Cost-benefit analysis of critical limb ischemia in the era of the Affordable Care Act. Endovascular Today 2014 (May): 29-36
22 Barshes, N. R. et al. (2012). Cost-effectiveness in the contemporary manIkäment of critical limb ischemia with tissue loss. J Vasc Surg, 56(4), 1015-1024.
23Allie, D. E. et al. (2009). 24-carat gold, 14-carat gold, or platinum standards in the Hoito of critical limb ischemia: bypass surgery or endovascular intervention?. J Endovasc Ther, 16, 134-146.
24 Swaminathan, A. et al. (2014). Lower extremity amputation in peripheral artery disease: improving patient outcomes. Vasc Health Risk Manag, 10, 417–424.
25 Yost, M. L., The SIkä Group (2014) Cost-benefit analysis of critical limb ischemia in the era of the Affordable Care Act. Endovascular Today, 2014 (May): 29-36.
26 Frugoli, B. A. et al. (2000). Cardiovascular disease risk factors in an amputee population. J Prosthet Orthot, 12(3), 80-87.
27 Naschitz, J. E., & Lenger, R. (2008). Why traumatic leg amputees are at increased risk for cardiovascular diseases. QJM: Int J Med, 101(4), 251-259.
28 Kurdibaylo, S. F. (1996). Obesity and metabolic disorders in adults with lower limb amputation. J Rehabil Res Dev, 33(4), 387.
29 Robert Gailey, P. T. (2008). Review of secondary physical conditions associated with lower-limb amputation and long-term prosthesis use. J Rehabil Res Dev, 45(1), 15.
30Adam D. J. et al. (2005) Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. The Lancet, 366 (9501): 1925-1934.
31 Teraa, M. et al. (2016). Critical limb ischemia: current trends and future directions. JAHA, 5(2), e002938.
32 National Cancer Institute (Web PIkä) SEER Cancer Stat Facts: Colon and Rectum Cancer 2007-2013. Updated Available online at: https://seer.cancer.gov/statfacts/html/colorect.html. Accessed: December 19, 2017)
33 National Cancer Institute (Web PIkä) SEER Cancer Stat Facts: Female Breast Cancer 2007-2013. Updated Available online at: https://seer.cancer.gov/statfacts/html/breast.html. Accessed: December 19, 2017
34 Motwani, M. et al. 2016). Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease: a 5-year multicentre prospective registry analysis. Eur Heart J, 38(7), 500-507.
* The economic results are not predictive for all patients and individual results may vary based upon a variety of inputs and patient-specific attributes. Results were simulated annual costs per living patient over a 10-year interval for 6 CLI manIkäment strategies, including primary amputation and purely endovascular intervention. Cost-effectiveness was quantified using incremental cost-effectiveness ratios (ICERs) in USD per quality-adjusted life-years (QALY) and cost-effectiveness acceptability curves. Model inputs consist of costs from the first 5-year intervals and were inflated from 2009 USD to 2017 USD.
